Experimental lung cancer drug trial halted early
NCT ID NCT06173505
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new immunotherapy drug called vudalimab combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It compared this combination to the standard treatment of pembrolizumab plus chemotherapy. The study was terminated early after enrolling only 28 people, so it is unclear if vudalimab offers any benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vudalimab (an experimental immunotherapy drug) combined with chemotherapy (carboplatin and pemetrexed)
- What this could lead to
- If successful, this could point toward a new first-line treatment option for advanced non-small cell lung cancer.
- What could go wrong
- This trial was terminated early with only 28 participants, so results are very limited. It is too early to know if vudalimab is safe or effective compared to existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSQUAMOUS NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changhua Christian Hospital
Changhua, 500, Taiwan
-
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360, United States
-
Hematology Associates of Fredericksburg
Fredericksburg, Virginia, 22408, United States
-
Hospital Clinic i Provincial de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Sultan Ismail
Johor Bahru, 81100, Malaysia
-
Hospital Umum Sarawak
Kuching, 93586, Malaysia
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Institut Català d'Oncolgia de Girona
Girona, 17007, Spain
-
Institut Kanser Negara
Putrajaya, 62250, Malaysia
-
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, 3500, Belgium
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
-
NEXT Oncology-Hospital Quirónsalud Barcelona
Barcelona, 08023, Spain
-
Palo Verde Cancer Specialists
Glendale, Arizona, 85304, United States
-
St. Lukes (Agios Loucas) Hospital
Thessaloniki, 552 36, Greece
-
The Netherlands Cancer Institute - Antoni van Leeuwenhoek
Amsterdam, North Holland, 1066 CX, Netherlands
-
ULS do Alto Ave, EPE - Hospital da Senhora da Oliveira Guimarães
Guimarães, 4835-044, Portugal
More trials for these conditions
Other studies related to the condition(s) this trial covers.